Alle publicaties

GLAGOVEffect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial

IMPORTANCE Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase […]

Odyssey Long TermEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Background   Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin– kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels […]

Jennifer G. Robinson, M.D., M.P.H., Michel Farnier, M.D., Ph.D., Michel Krempf, M.D., Jean Bergeron, M.D.,
Gérald Luc, M.D., Maurizio Averna, M.D., Erik S. Stroes, M.D., Ph.D., Gisle Langslet, M.D.,
Frederick J. Raal, M.D., Ph.D., Mahfouz El Shahawy, M.D., Michael J. Koren, M.D., Norman E. Lepor, M.D.,
Christelle Lorenzato, M.Sc., Robert Pordy, M.D., Umesh Chaudhari, M.D., and John J.P. Kastelein, M.D., Ph.D.,
for the ODYSSEY LONG TERM Investigators*

dal-OUTCOMESEffects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Background In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether […]

dal-VESSELVascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease

Aims High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular (CV) events and thus an attractive therapeutic target. However, in spite of marked elevations in HDL-C, […]

Thomas F. Lüscher 1*, Stefano Taddei 2, Juan-Carlos Kaski 3, J. Wouter Jukema 4, David Kallend 5, Thomas Münzel 6, John J.P. Kastelein 7, and John E. Deanfield 8, on behalf of the dal-VESSEL Investigators
1 Department of Cardiology, Cardiovascular Centre, University of Zurich, 8091 Zurich, Switzerland; Department of Internal Medicine, University of Pisa, Pisa, Italy; 3 Cardiovascular Sciences Research Centre, St George’s, University of London, London, UK; 4 Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; 5 Department of Medicine II, Johannes Gutenberg-University Mainz, Mainz, Germany; 6 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands; 7 F. Hoffmann-La Roche Ltd, Basle, Switzerland; and 8 University College, London, UK

EFJESafety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 (PCSK9)

Aims The objective of this study was to evaluate the efficacy, safety, and tolerability of LY3015014 (LY), a neutralizing antibody of proprotein convertase subtilisin/kexin type 9 […]

CHI-SQUAREEffects of the high-density lipoproteinmimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

Aim High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo. Objective To […]

Jean-Claude Tardif1*, Christie M. Ballantyne2, Philip Barter3, Jean-Louis Dasseux4, Zahi A. Fayad5, Marie-Claude Guertin1, John J. P. Kastelein6, Constance Keyserling4, Heather Klepp4,Wolfgang Koenig7, Philippe L. L’Allier1, Jacques Lespe´rance1, Thomas F. Lu¨ scher8, John F. Paolini4, Ahmed Tawakol9, and David D.Waters10, for the Can Hdl Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators

CHARONEfficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia

OBJECTIVE: Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder leading to premature atherosclerosis. Guidelines recommend initiating statins early to reduce lowdensity lipoprotein cholesterol (LDL-C). […]

ALECARDIOEffect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus

IMPORTANCE No therapy directed against diabetes has been shown to unequivocally reduce the excess risk of cardiovascular complications. Aleglitazar is a dual agonist of peroxisome […]

1 2 3 4